We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi Utah - agree, but it does make Thoth's long standing valuation of 28p look fairly achievable......
Roll on the 28p party......
Once we receive some further updates on the new 2019 TYK2 US patent application then this will also be transformational for SAR.
The new application cited a multitude of conditions/indications and diseases the compounds can be used to treat. All of these must have been assessed by SRI (their engagement was continued for further experiments) since the lupus report otherwise SAR could be accused of making false representation?????
66p hilarious . None of us would wait for 66p !any sniff of a deal that gives us 10p and there will be lots of sales . It’s pretty quiet again from company
It more like 12 years than 12 months to get to 65p.
Alot of traders been hear 8 years and long terms.
I will be more than happy with 10p.
Says it all about Parker!!!
Yes, Parkers wife invested all of £5k (less then 10% of what he was paid by the company)
And the problem with 12 months is the need for funding ... roll on the Sierra sale ... although confused why one board member buys $100K worth of shares but NG and others do not ...
I don't mind waiting 12 months for 65p. Lol. Seriously though, I can see where these valuations come from but I think if we want a quick deal with less risk. We'll be lucky to get 10p
Hi All - truly inspiring valuations!!
IMHO the TYK2 research paper and presentation currently under production for peer review will give us some long awaited insights to the ‘compelling data’ that TM often cites.
This coupled with an announcement/approval/commencement of Phase I trials will IMHO be a game changer. I’m with Potnak though and fear it will be another 12 + months before we see it. Happy to see it before though TM.......
GLA
It would give large holders like Thoth upwards of £27mil. It is possible if all came to fruition but Pharma is volatile.
I think it’s hard to put a value on SDC as a big company wanting could just buy the shares issue off shareholders, so what value would we ascribed to a product that is told is compelling without any third party Data to back up a valuation of it, most share holders would take a 5 bag easy as other posters have said, can’t see an untested product be that high until we know for certain that a big companies are looking at and are excited by what they see as more info is needed as Tim has eluded too!
The CHk1 is a different story altogether as it’s been derisked by Sierra because it’s safe and has efficacy and has the credibility of the clinical professional’s/institutions behind it and looks to do a good job which it is designed for a synthetic molecule that was created to potentates the effects of Gemicitabine too increase its potency, as we know LDG kills the cell and then try’s to repair itself by calling on mechanisms and is pushed into using chk1 to repair, there is other pathways as has been mentioned for repair networks ATR, WEE1 so the real power for SRA737 is in combination therapy here, so for me this is where the value is and is looking like can be effective in a range of cancer indications so what’s the price of that?
Wow that's the biggest guestimate I have seen for a while on this BB if not the biggest to be honest, even I would be a millionaire with that price God knows what the big holders would be. Bring it on, please.
After reading all your posts i come to the conclusion or my understanding is TYK2 1801 & 2 is valued at 1.6 billion entering into phase 1 trials and SRA 737 is valued at 200 million + thats a 200 bagger from this price.. gold mine. Is this optimistic or is this still an undervaluation ???